Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors

Sponsor
Exelixis
Study ID
NCT07773454
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer
  • Pediatric Cancer

Eligibility Criteria

Sex
ALL
Age
12 Months - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Administered as specified in the treatment arm.

Study Details

The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.

Key Dates

First listed
Aug 19, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zanzalintinib
    Participants will receive zanzalintinib oral tablets once daily (QD).

Primary Outcome Measure

Number of Participants With Dose-Limiting Toxicities (DLTs) [ Time Frame: Up to Day 28 ]

Central Contacts

Related Studies